<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03787680</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2018.108</org_study_id>
    <secondary_id>HUM00152799</secondary_id>
    <nct_id>NCT03787680</nct_id>
  </id_info>
  <brief_title>Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)</brief_title>
  <official_title>A Multi-Center Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness (how well the drugs work), safety, and&#xD;
      tolerability of the investigational drug combination of olaparib and AZD6738 for all patients&#xD;
      with metastatic castration-resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 31, 2019</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of response (Complete Response [CR] or Partial Response [PR]) in DNA repair proficient (DRPro) patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year)</time_frame>
    <description>Evaluated per radiographic response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or by Prostate Specific Antigen (PSA) (≥50% decline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of response (Complete Response [CR] or Partial Response [PR]) in DNA repair deficient (DRDef) patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Evaluated per radiographic response according to RECIST v1.1 or PSA (≥50% decline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) in DRPro patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Duration of time from start of treatment to time of progression (based only on radiographic progression or clinical decline/death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) in DRDef patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Duration of time from start of treatment to time of progression (based only on radiographic progression or clinical decline/death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic response rate in DRPro patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Evaluated according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic response rate in DRDef patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Evaluated according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA progression-free survival in DRPro patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Composite of survival and duration of PSA control as defined by time from start of therapy to first PSA increase ≥ 25% and ≥2 ng/ml above the nadir and confirmed by a second value at or beyond 4 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA progression-free survival in DRDef patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Composite of survival and duration of PSA control as defined by time from start of therapy to first PSA increase ≥ 25% and ≥2 ng/ml above the nadir and confirmed by a second value at or beyond 4 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate in DRPro patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Rate of achieving PSA response rate of ≤ 0.2 ng/ml, 50% decline, or 90% decline from entry PSA and confirmed 4 weeks later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate in DRDef patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Rate of achieving PSA response rate of ≤ 0.2 ng/ml, 50% decline, or 90% decline from entry PSA and confirmed 4 weeks later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of combined radiographic and PSA response in DRPro patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Time from first documented response (RECIST v1.1 CR/PR or PSA decline ≥50%) until death, recurrent or progressive disease (based on RECIST v1.1) or first PSA increase ≥ 25% and ≥2 ng/ml above the PSA nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of combined radiographic and PSA response in DRDef patients</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>Time from first documented response (RECIST v1.1 CR/PR or PSA decline ≥50%) until death, recurrent or progressive disease (based on RECIST v1.1) or first PSA increase ≥ 25% and ≥2 ng/ml above the PSA nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 30 days after study completion (an average of 1 year for study completion)</time_frame>
    <description>NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Myelodysplastic Syndrome (MDS), acute myeloid leukemia (AML) and new primary malignancy</measure>
    <time_frame>Up to 5 years after study completion (an average of 1 year for study completion)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (DRPro)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair proficient (DRPro).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (DRDef)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair deficient (DRDef).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>300 mg by mouth twice a day for days 1-28 of a 28-day cycle.</description>
    <arm_group_label>Cohort 1 (DRPro)</arm_group_label>
    <arm_group_label>Cohort 2 (DRDef)</arm_group_label>
    <other_name>AZD2281</other_name>
    <other_name>ceralasertib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6738</intervention_name>
    <description>160 mg by mouth daily for days 1-7 of a 28-day cycle.</description>
    <arm_group_label>Cohort 1 (DRPro)</arm_group_label>
    <arm_group_label>Cohort 2 (DRDef)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Male ages 18 years and older at time of signing the informed consent form&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 42 days&#xD;
             prior to registration&#xD;
&#xD;
          4. Histologic or cytologic proof of prostate adenocarcinoma (excluding small-cell or&#xD;
             neuroendocrine pathologies)&#xD;
&#xD;
          5. Metastatic prostate cancer on CT, MRI or Bone scan&#xD;
&#xD;
          6. Must have disease progression (while testosterone level is under 50 ng/dl) on prior&#xD;
             therapy prior to study entry defined as one (or more) of the following:&#xD;
&#xD;
               1. PSA progression defined as continuously rising PSA values measured a minimum of 1&#xD;
                  week apart with a minimal starting value of 1.0 ng/mL&#xD;
&#xD;
               2. Progression of bidimensionally measurable soft tissue or nodal metastasis by CT&#xD;
                  or MRI based on RECIST, v1.1&#xD;
&#xD;
          7. Prior treatment with at least one of the following:&#xD;
&#xD;
               1. One line of therapy in mCRPC&#xD;
&#xD;
               2. Second generation anti-androgen (e.g. abiraterone, enzalutamide or apalutamide)&#xD;
                  within the hormone-sensitive phase of disease AND progression occurs while on&#xD;
                  therapy&#xD;
&#xD;
          8. Patients must be withdrawn from prior therapy for ≥3 weeks (patients may remain on&#xD;
             prior prednisone up to 10 mg total daily exposure at provider's discretion) at planned&#xD;
             time of treatment start.&#xD;
&#xD;
          9. Agree to undergo a biopsy of at least one metastatic site (if feasible) to determine&#xD;
             DNA repair status, unless prior metastatic tissue underwent next-generation sequencing&#xD;
             in a CLIA certified lab or known germline loss of BRCA1, BRCA2 or ATM. If no site is&#xD;
             reachable, or first biopsy insufficient/unsuccessful, circulating tumor DNA may be&#xD;
             obtained.&#xD;
&#xD;
         10. Treated with continuous androgen deprivation therapy (either surgical castration or&#xD;
             LHRH agonist/antagonist) with documented castrate level of serum testosterone (&lt;50&#xD;
             ng/dL). A stable dose of bisphosphonate or denosumab for bone metastases should be&#xD;
             continued as long as started at least 5 days prior to C1D1 planned start day.&#xD;
&#xD;
         11. At the time of planned treatment start (C1D1), at least 21 or more days will have&#xD;
             elapsed from palliative radiation (with the exception of radiation to &gt;30% of bone&#xD;
             marrow or with a wide field of radiation, this requires 28 or more days).&#xD;
&#xD;
         12. Patient must have normal organ and bone marrow function measured within 42 days prior&#xD;
             to registration as defined below&#xD;
&#xD;
               1. Hemoglobin ≥10 g/dL (with no blood transfusion or erythropoietin use within the&#xD;
                  past 42 days)&#xD;
&#xD;
               2. Absolute neutrophil count ≥1.5x109/L&#xD;
&#xD;
               3. Platelet count ≥100x109/L (with no platelet transfusions within last 42 days)&#xD;
&#xD;
               4. Total bilirubin &lt;1.5x ULN (unless the patient has documented Gilbert's disease&#xD;
                  and &lt;2.0x ULN should be used)&#xD;
&#xD;
               5. AST or ALT ≤ 2.5x ULN, unless liver metastases are present in which case they&#xD;
                  cannot be ≥5x ULN&#xD;
&#xD;
               6. Glomerular filtration rate (GFR) ≥51 mL/min, as assessed using the Cockcroft-&#xD;
                  Gault equation&#xD;
&#xD;
         13. Estimated life expectancy ≥16 weeks&#xD;
&#xD;
         14. Male patients who are sexually active must be willing to use barrier contraception for&#xD;
             the duration of the study and for 1 week after the last study drug administration,&#xD;
             with all sexual partners. Male patients must use a condom during treatment and for 6&#xD;
             months after the last dose of study drug(s) when having sexual intercourse with a&#xD;
             pregnant woman or with a woman of childbearing potential and must not donate sperm for&#xD;
             6 months after the last dose of study drug. Female partners of male patients should&#xD;
             also use a highly effective form of contraception (per protocol) for 6 months after&#xD;
             the last dose of study drug(s) if they are of childbearing potential. True abstinence&#xD;
             is an acceptable form of contraception and must be documented as such.&#xD;
&#xD;
         15. Patient is willing and able to comply with the protocol for the duration of the study,&#xD;
             including undergoing biopsy (if warranted), treatment, scheduled visits and&#xD;
             examinations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of ataxia telangiectasia&#xD;
&#xD;
          2. Prior treatment with a PARP inhibitor (e.g. olaparib, veliparib, niraparib,&#xD;
             rucaparib), AZD6738 or other DNA-damage response agents (e.g. cisplatin or&#xD;
             carboplatin)&#xD;
&#xD;
          3. Cytotoxic chemotherapy, first- or second-generation antiandrogen or CYP17 inhibitors&#xD;
             are not permitted within 21 days or 5 half-lives of registration (whichever is&#xD;
             longest) of planned treatment start. For clarity, enzalutamide requires 5 weeks&#xD;
             washout.&#xD;
&#xD;
          4. Major surgery &lt; 2 weeks prior to enrolment; patients must have recovered from any&#xD;
             effects of major surgery&#xD;
&#xD;
          5. Persistent toxicities (≥CTCAE Grade 2) caused by previous cancer therapy, besides&#xD;
             Grade 2 alopecia and Grade 2 neuropathy (these are allowed).&#xD;
&#xD;
          6. Patients with current or prior MDS/AML or with features suggestive of MDS/AML&#xD;
&#xD;
          7. Any other malignancy which has been active or treated within the past 3 years, with&#xD;
             the exception of non-melanomatous skin cancer, or Ta bladder cancer&#xD;
&#xD;
          8. Patients with active brain metastases are excluded because of unknown penetration into&#xD;
             the CNS. A confirmatory scan for asymptomatic patients is not required. Patients with&#xD;
             a history of treated central nervous system (CNS) metastases are eligible provided&#xD;
             they meet all of the following criteria: disease outside the CNS is present, no&#xD;
             clinical evidence of progression since completion of CNS-directed therapy, minimum 3&#xD;
             weeks between completion of radiotherapy and registration and recovery from&#xD;
             significant (Grade ≥ 3) acute toxicity with no ongoing requirement for &gt;10 mg of&#xD;
             prednisone per day or an equivalent dose of other corticosteroid. If a patient must&#xD;
             remain on steroids, they must have started the steady dose at least 28 days prior to&#xD;
             treatment. Patients with spinal cord compression unless considered to have received&#xD;
             definitive treatment for this and evidence of clinically stable disease for 28 days&#xD;
             prior to study treatment.&#xD;
&#xD;
          9. Any of the following cardiac disease currently or within the last 6 months:&#xD;
&#xD;
               1. Unstable angina pectoris&#xD;
&#xD;
               2. Congestive heart failure (by New York Heart Association ≥ Class 2) or known&#xD;
                  reduced LVEF &lt; 55%&#xD;
&#xD;
               3. Acute myocardial infarction&#xD;
&#xD;
               4. Conduction abnormality not controlled with pacemaker or medication (e.g. complete&#xD;
                  left bundle branch block or third-degree heart block)&#xD;
&#xD;
               5. Significant ventricular or supraventricular arrhythmias (patients with chronic&#xD;
                  rate-controlled atrial fibrillation in the absence of other cardiac abnormalities&#xD;
                  are eligible).&#xD;
&#xD;
               6. Uncontrolled hypertension (Grade 2 or above) requiring urgent (for example,&#xD;
                  adjusting medications within 24 hours) clinical intervention&#xD;
&#xD;
               7. Patients at risk of brain perfusion problems, e.g. TIAs or history of pre-&#xD;
                  syncope or syncopal episodes unexplained by reversible causes&#xD;
&#xD;
         10. Mean resting corrected QT interval &gt;450, obtained from 3 ECGs 2-5 minutes apart using&#xD;
             the Fredericia formula. Absence of any factors that increase the risk of QTc&#xD;
             prolongation or risk of arrhythmic such as congenital long QT syndrome, immediate&#xD;
             family history of long QT syndrome or unexplained sudden death under 40 year of age.&#xD;
             Patients with relative hypotension (&lt;90/60 mmHg) or previously known clinically&#xD;
             relevant orthostatic hypotension defined as a postural hypotension ≥20 mmHg&#xD;
&#xD;
         11. Concomitant use of known potent or moderate cytochrome P (CYP) 3A inhibitors (e.g.&#xD;
             itraconazole, ciprofloxacin, diltiazem) require 2-week washout prior to planned C1D1.&#xD;
             Concomitant use of strong or moderate CYP3A inducers (e.g. phenobarbital,&#xD;
             enzalutamide, modafinil require 5-week washout for enzalutamide or phenobarbital and 3&#xD;
             week washout for all others, per protocol.&#xD;
&#xD;
         12. As judged by the Investigator, any evidence of severe or uncontrolled systemic&#xD;
             diseases that places the patient at unacceptable risk of toxicity or non-compliance.&#xD;
             Examples include, but are not limited to, active bleeding diatheses, renal transplant,&#xD;
             uncontrolled major seizure disorder, severe COPD, superior vena cava syndrome,&#xD;
             extensive bilateral lung disease on High Resolution CT scan, severe Parkinson's&#xD;
             disease, active inflammatory bowel disease, psychiatric condition, immunocompromised&#xD;
             patients or active infection including any patient known to have hepatitis B,&#xD;
             hepatitis C and human immunodeficiency virus (HIV) or requiring systemic antibiotics,&#xD;
             antifungals or antiviral drugs. Screening for chronic conditions is not required&#xD;
&#xD;
         13. A known hypersensitivity to olaparib, AZD6738 or any excipient of the product or any&#xD;
             contraindication to the combination anti-cancer agent as per local prescribing&#xD;
             information&#xD;
&#xD;
         14. Patients unable to swallow orally administered medication and patients with&#xD;
             gastrointestinal disorders likely to interfere with the absorption of the study&#xD;
             medication, refractory nausea and vomiting, chronic gastrointestinal diseases or&#xD;
             previous significant bowel resection, with clinically significant sequelae that would&#xD;
             preclude adequate absorption of AZD6738&#xD;
&#xD;
         15. Previous allogenic bone marrow transplant or double umbilical cord blood&#xD;
             transplantation (dUCBT).&#xD;
&#xD;
         16. Whole blood transfusions in the last 120 days prior to entry to the study (packed red&#xD;
             blood cells and platelet transfusions are acceptable, for timing refer to inclusion&#xD;
             criteria no.12)&#xD;
&#xD;
         17. Involvement in the planning and/or conduct of the study&#xD;
&#xD;
         18. Judgment by the investigator that the patient should not participate in the study if&#xD;
             the patient is unlikely to comply with study procedures, restrictions and&#xD;
             requirements.&#xD;
&#xD;
         19. Previous enrolment in the present study.&#xD;
&#xD;
         20. Has received a live vaccination with 2 weeks of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachery Reichert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 24, 2018</study_first_submitted>
  <study_first_submitted_qc>December 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

